Quick Answer
Calidi Biotherapeutics, Inc. reported Total Assets of $8.86 million for fiscal year 2025.
Calidi Biotherapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $8.86M | -37.5% |
| 2024 | $14.18M | +41.6% |
| 2023 | $10.02M | +285.8% |
| 2022 | $2.60M | -98.9% |
| 2021 | $231.77M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.03M | +110.7% | +50.0% |
| June 30, 2025 | $9.35M | +45.4% | -37.9% |
| March 31, 2025 | $15.06M | +103.4% | +6.2% |
| December 31, 2024 | $14.18M | +41.6% | +113.0% |
| September 30, 2024 | $6.66M | -64.2% | +3.5% |
| June 30, 2024 | $6.43M | -85.4% | -13.2% |
| March 31, 2024 | $7.41M | -82.8% | -26.1% |
| December 31, 2023 | $10.02M | +285.8% | -46.1% |
- Calidi Biotherapeutics, Inc. showed a decrease of -37.5% in Total Assets compared to the prior fiscal year.
- Over the 2021–2025 period, Calidi Biotherapeutics, Inc.’s total assets has declined by 96.2% (from $231.77 million to $8.86 million).
- The most recent figure is from Calidi Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: